



# PATENT

**Burkly, Linda C.**

### Before the Examiner:

### Group Art:

**For: TREATMENT FOR INSULIN  
DEPENDENT DIABETES**

**Honorable Commissioner of Patents and Trademarks**  
**Washington, D.C. 20231**

This Information Disclosure Statement is filed under 37 C.F.R. §§ 1.97-1.98 in compliance with the duty of disclosure set forth in 37 C.F.R. §1.56.

In the judgment of the undersigned, the references listed on the attached Form PTO-1449, attached hereto, may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative

relevance of any portion of the references or as to the relative relevance (as between references, whether cited in this statement or prior statements). This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

## **II. LIST OF REFERENCES**

### **OTHER DOCUMENTS**

1. Castano and Eisenbarth, 1990, Annu. Rev. Immunology 8: 647-679, "Type I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat"
2. Fujita et al., 1982, Biomed. Res. 3: 429-443, "Lymphocytic Insulitis in a 'Non-obese Diabetic (NOD)' Strain of Mice: An Immunohistochemical and Electron Microscope Investigation"
3. Foulis et al., 1986, Diabetologia 29: 267-274, "The Histopathology of the Pancreas in Type 1 (Insulin-Dependent) Diabetes Mellitus: A 25-Year Review of Deaths in Patients Under 20 Years of Age in the United Kingdom"
4. Eisenbarth, 1986, New Engl. J. Med. 314: 1360-1368, "Type I Diabetes Mellitus - A Chronic Autoimmune Disease"
5. Miller et al., 1988, J. Immunol. 140: 52-58, "Both the Lyl-2<sup>+</sup> and L3T4<sup>+</sup> T Cell Subsets are Required for the Transfer of Diabetes in Nonobese Diabetic Mice"
6. Harada and Makino, 1986, Exp. Anim. 35: 501-504, "Suppression of Overt Diabetes in NOD Mice by Anti-Thymocyte Serum or Anti-Thy 1.2 Antibody"
7. Koike et al., 1987, Diabetes 36: 539-541, "Preventive Effect of Monoclonal Anti-L3T4 Antibody on Development of Diabetes in NOD Mice"

8. Makino et al., 1986, Exp. Anim. 35: 495-498, "Absence of Insulitis and Overt Diabetes in Athymic Nude Mice with NOD Genetic Background"
9. Voorbij et al., 1989, Diabetes 35: 1623-1629, "Dendritic Cells and Scavenger Macrophages in Pancreatic Islets of Prediabetic BB Rats"
10. Nomikos et al., 1986, Diabetes 35: 11302-1304, "Combined Treatment With Nicotinamide and Desferrioxamine Prevents Islet Allograft Destruction in NOD Mice"
11. Larson and Springer, 1990, Immunol. Rev. 114: 181-217, "Structure and Function of Leukocyte Integrins"
12. Hemler et al., 1990, Immunol. Rev. 114: 45-65, "Structure of the Integrin VLA-4 and its Cell-Cell and Cell-Matrix Adhesion Functions"
13. Lobb, 1992, in Adhesion: Its Role in Inflammatory Disease, pp. 1-18 (J.M. Harlan and D.Y. Liu, eds., New York: W. H. Freeman), "Integrin-Immunoglobulin Superfamily Interactions in Endothelial-Leukocyte Adhesion"
14. Osborn, 1990, Cell 62: 3-6, "Leukocyte Adhesion to Endothelium in Inflammation"
15. Wayner et al., 1989, J. Cell. Biol. 109: 1321-1330, "Identification and Characterization of the T Lymphocyte Adhesion Receptor for an Alternative Cell Attachment Domain (CS-1) in Plasma Fibronectin"
16. Shimizu et al., 1991, J. Cell Biol. 113: 1203-1212, "Four Molecular Pathways to T Cell Adhesion to Endothelial Cells: Roles of LFA-1 VCAM-1 and ELAM-1 and Changes in Pathway Hierarchy Under Different Activation Conditions"
17. Barton et al., 1989, J. Immunol. 143: 1278-1282, "The Effect of Anti-Intercellular Adhesion Molecule-1 on Phorbol-Induced Rabbit Lung Inflammation"

18. Issekutz, and Issekutz, 1991, Clinical Immunol. and Immunopathol. 61: 436-447, "T Lymphocyte Migration to Arthritis Joints and Dermal Inflammation in the Rat: Differing Migration Patterns and the Involvement of VLA-4"
19. Issekutz, 1991, J. Immunol 147: 4178-4184, "Inhibition of In Vivo Lymphocyte Migration to Inflammation and Homing to Lymphoid Tissues by the TA-2 Monoclonal Antibody - A Likely Role for VLA-4 In Vivo"
20. \*Yednock et al., 1992, Nature 356: 63-66, "Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies Against  $\alpha 4\beta 1$  Integrin"
21. Dustin et al., 1986, J. Immunol. 137: 245-254 "Induction by IL-1 and Interferon- $\gamma$  Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (ICAM-1)"
22. Rice et al., 1990, J. Exp. Med. 171: 1369, "Inducible Cell Adhesion Molecule 110 (INCAM-110) Is An Endothelial Receptor for Lymphocytes - A CD11/CD18-Independent Adhesion Mechanism"
23. Rice et al., 1991, Am. J. Path. 138: 385-393, "Vascular and Nonvascular Expression of INCAM-110"
24. Shimuzu et al., 1990, Immunol. Rev. 114: 109-143, "Roles of Adhesion Molecules in T-Cell Recognition: Fundamental Similarities Between Four Integrins on Resting Human T Cells (LFA-1, VLA-4, VLA-5, VLA-6) in Expression, Binding and Costimulation"

---

\* Applicant believes this document may be relatively more pertinent than other of the references cited herein.

25. Burkly et al., 1991, Eur. J. Immunol. 21: 2871-2875, "Signaling by Vascular Cell Adhesion Molecule-1 (VCAM-1) Through VLA4 Promotes CD3-Dependent T Cell Proliferation"
26. Rudd et al., 1989, Immunol. Rev. 111: 225-266, "Molecular Interactions, T-Cell Subsets, and a Role of the CD4/CD8:p56<sup>lck</sup> Complex in Human T-Cell Activation"
27. Moingeon et al., 1989, Immunol. Rev. 111: 111-144, "The Structural Biology of CD2"
28. Harding et al., 1992, Nature 356: 607-609, "CD28-Mediated Signalling Co-Stimulates Murine T Cells and Prevents Induction of Energy in T Cell Clones"
29. Shizuru et al., 1988, Science 240: 659-662, "Immunotherapy of the Nonobese Diabetic Mouse: Treatment with an Antibody to T-Helper Lymphocytes"
30. Barlow and Like, 1992, Amer. J. Pathol. 141: 1043-1051, "Anti-CD2 Monoclonal Antibodies Prevent Spontaneous and Adoptive Transfer of Diabetes in the BB/Wor Rat"
31. Like et al., 1986, J. Exp. Med. 164: 1145-1159, "Prevention of Diabetes in Biobreeding/Worcester Rats with Monoclonal Antibodies that Recognize T Lymphocytes or Natural Killer Cells"
32. \*Hutchings et al., 1990, Nature 348: 639-642, "Transfer of Diabetes in Mice Prevented by Blockade of Adhesion-Promoting Receptor on Macrophages"
33. Federlin and Becker, 1990, Klin. Wochenschr. 68: Suppl. XXI 38-43, "Specific Therapeutic Attempts in Experimental and Clinical Type-I Diabetes"

34. Zielasek et al., 1989, Clin. Immunol. Immunopathol. 52: 347-365, "The Potentially Simple Mathematics of Type I Diabetes"
35. Eisenbarth, 1987, Hosp. Prac. 22:167-184, "Type I Diabetes: Clinical Implication of Autoimmunity"
36. Ziegler and Eisenbarth, 1990, Horm. Res. 33: 144-150, "Multiple Target Antigens in Pre-Type I Diabetes: Implications for Prediction"
37. Ziegler et al., 1990, Diabetes Care 13: 762-765, "Predicting Type I Diabetes"
38. Ziegler et al., 1990, J. Autoimmun. 3 Suppl. 1: 69-74, "Type I Diabetes: Polygenic Inheritance, Multiple Autoantigens and 'Dual' Parameter Prediction"
39. Kohler and Milstein, 1975, Nature 265: 495-497, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity"
40. Sanchez-Madrid et al., 1986, Eur. J. Immunol., 16: 1343-1349, "VLA-3: A Novel Polypeptide Association Within the VLA Molecular Complex: Cell Distribution and Biochemical Characterization"
41. Hemler et al., 1987, J. Biol. Chem. 262: 11478-11485, "Characterization of the Cell Surface Heterodimer VLA4 and Related Peptides"
42. Elices et al., 1990, Cell 60: 577-584, "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA4 at a Site Distinct from the VLA4/Fibronectin Binding Site"
43. Pulido et al., 1991, J. Biol. Chem., 266(16): 10241-10245, "Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4"

44. Boerner et al., 1991, J. Immunol. 147: 86-95, "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes"
45. Persson et al., 1991, Proc. Natl. Acad. Sci. USA 88: 2432-2436, "Generation of Diverse High-Affinity Human Monoclonal Antibodies by Repertoire Cloning"
46. Huang and Stollar, 1991, J. Immunol. Methods 141: 227-236, "Construction of Representative Immunoglobulin Variable Region cDNA Libraries from Human Peripheral Blood Lymphocytes Without In Vitro Stimulation"
47. Jones et al., 1986, Nature 321: 522-525, "Replacing the Complementarity-Determining Regions in a Human Antibody With Those from a Mouse"
48. Riechmann, 1988, Nature 332: 323-327, "Reshaping Human Antibodies for Therapy"
49. Queen et al., 1989, Proc. Natl. Acad. Sci. USA 86:10029-10033, "A Humanized Antibody That Binds to the Interleukin 2 Receptor"
50. Orlandi et al., 1989, Proc. Natl. Acad. Sci. USA 86:3833-3837 "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction"
51. Holzmann et al, 1989, Cell 56: 37-46, "Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with  $\alpha$  Chain Homologous to Human VLA-4 $\alpha$ "
52. Hession et al., 1992, Biochem. Biophys. Res. Commun. 183: 163-169, "Cloning of Murine and Rat Vascular Cell Adhesion Molecule-1"
53. \*Yurochko et al., 1992, Proc. Natl. Acad. Sci. 89: 9034-9038, "Integrins as a Primary Signal Transduction Molecule Regulation Monocyte Immediate-Early Gene Induction"

54. Baron et al., 1993, J. Exp. Med. 177: 57-68, "Surface Expression of  $\alpha 4$  Integrin by CD4 T Cells Is Required for Their Entry into Brain Parenchyma"

Applicants respectfully request that these documents: (1) be fully considered by the Examiner during examination of this application; and (2) be listed on any "Notice of References Cited" issued in this application; and (3) be printed on any patent that may issue from this application.

Respectfully submitted,

ALLEGRETTI & WITCOFF, LTD.

By: Janet M. McNicholas

Janet M. McNicholas  
Reg. No. 32,918  
10 South Wacker Drive  
Chicago, Illinois 60606  
(312) 715-1000

Date: April 28, 1993





CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT, Form PTO-1449 (4 pages) and COPIES OF CITED REFERENCES (54)**, is being deposited with the United States Postal Service, as first class mail, in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on this 28th day of April, 1993.

By: Janet M. McNicholas  
Janet M. McNicholas